Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.43 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | KIF5B | P33176 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 4/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | PAK4 | O96013 | 7/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876350 | 0.94 | RET (0.43) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25884653 | 0.91 | RET (0.42) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25884650 | 0.84 | RET (0.42) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25875934 | 0.82 | RET (0.44) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL24668011 | 0.81 | AURKA (0.53) | JAK2AURKAAURKBJAK1TYK2 | |
| SCHEMBL28411559 | 0.80 | RET (0.44) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL30250267 | 0.80 | RET (0.44) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25876287 | 0.79 | RET (0.43) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25875746 | 0.79 | RET (0.46) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25876326 | 0.79 | RET (0.44) | JAK2RETKIF5BKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | JAK2 38/4885RET 1/4885KIF5B 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.